In Response to: 'Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?'

Authors :: Nicholas J. Thomas
Nathaniel J. Myall
Fangdi Sun
Tejas Patil
Rao Mushtaq
Chandler Yu
Sumi Sinha
Erqi L. Pollom
Seema Nagpal
D. Ross Camidge
Chad G. Rusthoven
Steve E. Braunstein
Heather A. Wakelee
Caroline E. McCoach
Source :: Journal of Thoracic Oncology. 17:e12-e14
Publication Year :: 2022
Publisher :: Elsevier BV, 2022.

Subjects :: ErbB Receptors
Pulmonary and Respiratory Medicine
Lung Neoplasms
Oncology
Brain Neoplasms
Carcinoma, Non-Small-Cell Lung
Humans
Receptor Protein-Tyrosine Kinases

Tools